The stock of Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) last traded at $2.19, down -1.35% from the previous session.
Data from the available sources indicates that Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) is covered by 3 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $2.15, we find $2.15. Given the previous closing price of $2.22, this indicates a potential downside of -3.15 percent. PRTK stock price is now 13.60% away from the 50-day moving average and -0.26% away from the 200-day moving average. The market capitalization of the company currently stands at $126.60M.
In total, 2 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $3.10 as their price target over the next twelve months.
In other news, DONDERO JAMES D, 10% Owner bought 100,000 shares of the company’s stock on Mar 23. The stock was bought for $173,000 at an average price of $1.73. Upon completion of the transaction, the 10% Owner now directly owns 2,156,000 shares in the company, valued at $4.72 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 22, 10% Owner DONDERO JAMES D bought 106,000 shares of the business’s stock. A total of $187,620 was incurred on buying the stock at an average price of $1.77. This leaves the insider owning 2,056,000 shares of the company worth $4.5 million. Insiders disposed of 442,492 shares of company stock worth roughly $0.97 million over the past 1 year. A total of 7.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PRTK stock. A new stake in Paratek Pharmaceuticals Inc. shares was purchased by CARLYLE GROUP INC. during the first quarter worth $2,280,000. EVERSEPT PARTNERS, LP invested $1,398,000 in shares of PRTK during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Paratek Pharmaceuticals Inc. valued at approximately $40,000. BAADER BANK AKTIENGESELLSCHAFT acquired a new stake in PRTK for approximately $25,000. CUTTER & CO BROKERAGE, INC. purchased a new stake in PRTK valued at around $24,000 in the second quarter. In total, there are 98 active investors with 46.40% ownership of the company’s stock.
With an opening price of $2.2100 on Thursday morning, Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) set off the trading day. During the past 12 months, Paratek Pharmaceuticals Inc. has had a low of $1.29 and a high of $3.65. The fifty day moving average price for PRTK is $1.9346 and a two-hundred day moving average price translates $2.1934 for the stock.
The latest earnings results from Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.35, beating analysts’ expectations of -$0.42 by 0.07. This compares to -$0.34 EPS in the same period last year. The net profit margin was -39.50% and return on equity was 39.00% for PRTK. The company reported revenue of $31.24 million for the quarter, compared to $24.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.64 percent. For the current quarter, analysts expect PRTK to generate $33.85M in revenue.
Moreover, the firm recently paid out its quarterly dividend on 10/29/2014. Investors who held shares on 10/24/2014 were paid a $0.6674 dividend.
Paratek Pharmaceuticals Inc.(PRTK) Company Profile
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.
